| Sign In to gain access to subscriptions and/or personal tools. |
Optimizing Higher Throughput Methods to Assess Drug-Drug Interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 In Vitro Using a Single Point IC50Pfizer Global Research and Development, Groton, CT
Pfizer Global Research and Development, Groton, CT
Concurrent Pharmaceuticals, Inc, Cambridge, MA
Pfizer Global Research and Development, Groton, CT
Pfizer Global Research and Development, Groton, CT
Pfizer Global Research and Development, Groton, CT
Pfizer Global Research and Development, Groton, CT Drug-drug interactions involving cytochrome P450 (CYP) are an important factor in whether a new chemical entity will survive through to the development stage. Therefore, the identification of this potential as early as possible in vitro could save considerable future unnecessary investment. In vitro CYP interaction screening data generated for CYP2C9, CYP2D6, and CYP3A4 were initially analyzed to determine the correlation of IC50 from 10- and 3-point determinations. A high correlation (r = 0.99) prompted the further assessment of predicting the IC50 by a single value of percent inhibition at either 10, 3, or 1 AM. Statistical analysis of the initial proprietary compounds showed that there was a strong linear relationship between log IC50 and percent inhibition at 3,M, and that it was possible to predict a compound's IC50 by the percent inhibition value obtained at 3 AM. Additional data for CYP1A2, CYP2C19, and the recombinant CYP2D6 were later obtained and used together with the initial data to demonstrate that a single statistical model could be applicable across different CYPs and different in vitro microsomal systems. Ultimately, the data for all five CYPs and the recombinant CYP2D6 were used to build a statistical model for predicting the IC50 with a single point. The 95% prediction boundary for the region of interest was about + 0.37 on log10 scale, comparable to the variability of in vitro determinations for positive control IC50 data. The use of a single inhibitor concentration would enable determination of more IC50 values on a 96-well plate and result in more economical use of compounds, human liver or expressed enzyme microsomes, substrates, and reagents. This approach would offer the opportunity to increase screening for CYP-mediated drug-drug interactions, which may be important given the challenges provided by the generation of orders of magnitude more new chemical entities in the field of combinatorial chemistry. In addition, the algorithmic approach we propose would obviously be applicable for other in vitro bioactivity and therapeutic target enzyme and receptor screens.
Journal of Biomolecular Screening, Vol. 7, No. 4,
373-382 (2002) This article has been cited by other articles:
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
 |
|
Sign In to gain access to subscriptions and/or personal tools.
